Barcelona (Spain), November 16, 2026. We are already present at MEDICA2026, the leading international event for the medical and healthcare technology sector. Throughout the exhibition, our team is welcoming professionals and strategic partners at Hall 1, Booth D33 to present the MAP-AD® test in detail.
MAP-AD® is a CE-IVDR marked prognostic blood test designed to predict the progression of Mild Cognitive Impairment (MCI) to Alzheimer’s dementia. To achieve this, it combines the analysis of novel mitochondrial epigenetic biomarkers with the patient’s clinical data using a machine-learning approach.
Anticipating progression for better clinical management
Thanks to this integration of molecular biology and artificial intelligence, MAP-AD® helps medical professionals anticipate clinical progression, enabling earlier, more precise, and informed patient management.
Come meet us at Hall 1, Booth D33
If you are visiting the exhibition, stop by our booth to discover the capabilities of our test firsthand. Our International Business Developer, Lee Creaser, is available at the event to meet with you and discuss how we can bring precision prognosis to your laboratory or healthcare network.
